New hepatitis C drugs are costing Medicare billions
Medicare spent $4.5 billion last year on new, pricey medications that cure the liver disease hepatitis C — more than 15 times what it spent the year before on older treatments for the disease, previously undisclosed federal data shows. The ...
Washington Post - Sun, 29 Mar 2015 19:02

New hepatitis C drugs cost government $4.5B
The Hill - Mon, 30 Mar 2015 05:53

New hepatitis C drugs costing Medicare billions
Dallas Morning News - Sun, 29 Mar 2015 20:56

Hepatitis C Drugs Cost Medicare $4.5B
Daily Beast - Sun, 29 Mar 2015 23:40

The Cost of a Cure: Medicare Spent $4.5 Billion on New Hepatitis C Drugs Last ...
ProPublica - Sun, 29 Mar 2015 19:03



Needle Exchanges Gain Currency
Evidence that HIV and hepatitis C are spreading among intravenous drug users is prompting more state and local officials to consider setting up needle exchanges—including some who had been resistant to such programs. The problem comes in tandem ...
Wall Street Journal - Sun, 29 Mar 2015 16:52

HAYDEN: HIV outbreak only part of a rural health crisis
Newsandtribune - Sat, 28 Mar 2015 08:56

HIV Outbreak Hits American Heartland
Frontline Desk - Fri, 27 Mar 2015 13:48



FDA Warns of Cardiac Effect When Heart Drug Mixed With Hepatitis C Meds ...
WEDNESDAY, March 25, 2015 (HealthDay News) -- A potentially life-threatening slowing of the heart can occur when the common heart drug amiodarone is taken with new hepatitis C medications, the U.S. Food and Drug Administration warns.
WebMD - Thu, 26 Mar 2015 07:26

FDA warns of serious bradycardia risk with amiodarone plus hepatitis C drugs
American Pharmacists Association, pharmacist.com - Wed, 25 Mar 2015 06:18

FDA: Avoid amiodarone use in patients prescribed hepatitis C meds
Clinical Advisor - Thu, 26 Mar 2015 07:34



Gileads Hepatitis C Drug Sovaldi Gets Approval in Japan
Gilead Sciences, Inc. (GILD - Analyst Report) announced that the Japanese Ministry of Health, Labour and Welfare has approved its hepatitis C virus (HCV) drug Sovaldi for the suppression of viremia in patients suffering from genotype 2 chronic HCV ...
Zacks.com - Fri, 27 Mar 2015 10:55

Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog
Nasdaq - Fri, 27 Mar 2015 10:48

Gilead Sciences: Big in Japan?
Barron's (blog) - Thu, 26 Mar 2015 07:23



Hepatitis C drug: From Rs 1.8 crore to Rs 1.2 Lakh
For around 2 crore Indians affected with Hepatitis C, there's finally a 'vial' of hope. Till a few weeks ago, Sofosbuvir – the only cure – was out of bounds for many. A six-month treatment would mean Rs 1.8 crore. It's now Rs 1.2 lakh, with US-based ...
Daily News & Analysis - Sun, 29 Mar 2015 16:37

Cipla Launches Hepatitis C Drug In India
Health Aim - Sun, 29 Mar 2015 04:15

Strides Arcolab Gains on Launch of Generic Drug
NDTV - Sun, 29 Mar 2015 22:20

Strides Arcolab stock up 3%
Indiainfoline - Sun, 29 Mar 2015 22:04



Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
Gilead Sciences' (NASDAQ: GILD ) stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going ...
Motley Fool - Sun, 29 Mar 2015 06:52

Lack of insurance bars some from hepatitis C treatment
Recently, more effective and well-tolerated drugs have been developed to treat hepatitis C, removing many of the discouraging side effects of older drugs. The infection is curable and transmission can be prevented, researchers write in the American ...
Reuters - Tue, 24 Mar 2015 08:11



Hepatitis C treatment: KP hospitals receive interferon after two years
The interferon drought occurred when the court took notice of substandard hepatitis C medicine being administered at hospitals in 2013. While the case is still sub-judice, sources say over 45,000 patients have hepatitis C in the province and the ...
The Express Tribune - Sun, 29 Mar 2015 11:29


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014